Division of Cardiac Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
COPPER Laboratory, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Artif Organs. 2024 Dec;48(12):1467-1475. doi: 10.1111/aor.14829. Epub 2024 Aug 12.
Ex vivo lung perfusion (EVLP) conducted outside of the transplant center has increased in recent years to mitigate its limitation by resources and expertise. We sought to evaluate EVLP performed at transplant centers and externally.
Lung transplant recipients were identified from the United Network for Organ Sharing Database. Recipients were then stratified into two groups based where they were perfused: Transplant Program (TP) or External Perfusion Centers (EPC). The groups were assessed with comparative statistics and long-term survival was assessed by Kaplan-Meier method. The groups were then 1:1 propensity and this process was repeated.
EPC use was generally restricted to the Southern United States. Following matching, there were no significant differences in post-operative outcomes to include post-operative stroke, dialysis, airway dehiscence, ECMO use, ventilator use or incidence of primary graft dysfunction Grade 3. Adjusted 3-year survival was 68.9% (95% Confidence Interval [CI]: 60.9%-77.9%) for the TP group and 67.6% (95% CI: 61.0%-74.9%) for the EPC group (p = 0.69). In allografts with extended ischemia (14+ h), those in the TP group had significantly longer length of stay, prolonged ventilation and treated rejection in the 1st year, though no significant difference in mid-term survival (p = 0.66).
EVLP performed at an EPC can be carried out with results and survival similar to allografts undergoing EVLP at a TP. EPCs will extend the valuable resource of EVLP to lung transplant programs without the resources to perform EVLP.
近年来,体外肺灌注(EVLP)在移植中心外的应用有所增加,以缓解其资源和专业知识的限制。我们旨在评估在移植中心和外部进行的 EVLP。
从器官共享联合网络数据库中确定肺移植受者。然后根据他们接受灌注的地点将受者分为两组:移植项目(TP)或外部灌注中心(EPC)。通过比较统计学方法评估两组,通过 Kaplan-Meier 方法评估长期生存率。然后对两组进行 1:1 倾向评分匹配,并重复此过程。
EPC 的使用通常仅限于美国南部。匹配后,包括术后中风、透析、气道裂开、ECMO 使用、呼吸机使用或原发性移植物功能障碍 3 级在内的术后结局没有显著差异。调整后的 3 年生存率为 TP 组的 68.9%(95%置信区间[CI]:60.9%-77.9%)和 EPC 组的 67.6%(95% CI:61.0%-74.9%)(p=0.69)。对于缺血时间延长(14+ 小时)的同种异体移植物,TP 组的住院时间更长,通气时间延长,第 1 年治疗排斥反应,但中期生存率无显著差异(p=0.66)。
在 EPC 进行的 EVLP 可以与在 TP 进行的 EVLP 的同种异体移植物的结果和存活率相似。EPC 将为没有进行 EVLP 资源的肺移植计划扩展宝贵的 EVLP 资源。